1093100-40-3 Usage
Uses
Used in Cancer Research and Treatment:
B-Raf inhibitor 1 is used as a therapeutic agent for targeting cancers with B-Raf gene mutations, particularly melanoma skin cancer. It functions by binding to the ATP-binding site of the B-Raf protein, thereby inhibiting the signal transduction pathway and the proliferation of cancerous cells.
Used in Drug Development:
B-Raf inhibitor 1 is used as a research tool in the development of new cancer treatments. It helps researchers understand the role of B-Raf protein kinase in cancer cell proliferation and the potential for targeted therapies to inhibit this process.
Used in Drug Resistance Studies:
B-Raf inhibitor 1 is used as a model compound in studying the development of drug resistance in cancer cells. By examining the effects of its misuse or overuse, researchers can gain insights into the mechanisms of resistance and work towards developing strategies to overcome it.
Used in Toxicity Assessment:
B-Raf inhibitor 1 is used in toxicological studies to evaluate the potential toxicity of this class of compounds. Understanding the risks associated with its use can inform the development of safer and more effective cancer treatments.
Check Digit Verification of cas no
The CAS Registry Mumber 1093100-40-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,9,3,1,0 and 0 respectively; the second part has 2 digits, 4 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1093100-40:
(9*1)+(8*0)+(7*9)+(6*3)+(5*1)+(4*0)+(3*0)+(2*4)+(1*0)=103
103 % 10 = 3
So 1093100-40-3 is a valid CAS Registry Number.
1093100-40-3Relevant academic research and scientific papers
RAF KINASE MODULATORS AND METHODS OF USE
-
Page/Page column 75, (2009/01/24)
The present invention comprises a new class of compounds capable of modulating the activity of Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have a general Formula (I) wherein each of A1, A2, A3, A4, A5, A6, A7, A8, A9, bond B, X, rings Z1 and Z2, R1 and R3 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of Raf kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.
